ADTRAN
16.7.2024 14:01:35 CEST | Business Wire | Press release
Adtran today announced that telMAX is leveraging its scalable, programmable fiber access technology as it extends its high-speed broadband services to many more communities. The Canadian service provider is harnessing Adtran’s Mosaic CP microservices platform integrated with GLDS BroadHub® subscriber management platform to enable rapid, cost-effective expansion of its network. With advanced automation features, the technology streamlines network management and service activation, empowering telMAX to enhance service delivery, troubleshooting and customer care. The new solution is built on Adtran’s compact SDX 6000 Series of Combo PON optical line terminals (OLTs), along with Adtran’s multigigabit XGS-PON optical network terminals, designed for the most bandwidth-intensive subscribers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716856855/en/
Adtran’s fiber access technology is helping telMAX rapidly expand into new areas. (Photo: Business Wire)
“At telMAX, our mission is to be the premier telecommunications provider in Canada, offering the fastest internet services and the best customer care experience. Leveraging Adtran’s technology has been instrumental in this goal. It’s enabled us to deliver exceptional speed and service, helping us earn recognition from PCMag as Canada’s Fastest ISP for the last two years running,” said Stuart Robert, president of telMAX. “Our new fiber access solution empowers us to perform many operations remotely, ensuring swift, trouble-free installations for our subscribers. The capability to quickly deploy and activate equipment optimizes productivity and significantly reduces manual efforts and operational costs. This efficiency enables us to rapidly expand into new areas, creating ‘fiberhoods’ where residents can enjoy exclusive, lightning-fast internet connectivity.”
telMAX is extending its network to reach more communities across the Greater Toronto Area. Today, they serve a growing customer base in the areas of Newmarket, Stouffville, Brooklin and Aurora. Leveraging Adtran’s technology, including the Mosaic CP platform and SDX Series of OLTs integrated with the GLDS BroadHub® subscriber management and service delivery platform, telMAX is well-equipped to meet the demands of these new markets. The integration allows for real-time adjustments to network conditions and rapid responses to customer demands, significantly enhancing operational efficiencies and scalability. It eliminates swivel-chair operations, removing operational barriers that can slow down workflows, complicate fiber rollouts and introduce friction into customer interactions. By enhancing service quality, minimizing downtime and ensuring heightened network reliability, telMAX will be able to provide superior connectivity and support to its expanding customer base.
“This deployment gives telMAX a more agile and customer-focused network, significantly increasing overall satisfaction as they bring ultra-fast full-fiber broadband to more households and businesses in Southern Ontario,” commented John Scherzinger, GM of Americas sales at Adtran. “Our technology is powering telMAX’s rapid growth, enabling them to expand their network while fostering community development. Seamless connectivity, reaching every street and neighborhood, will bridge the connectivity gap and enhance community engagement. Today’s digitally driven world demands intelligent, flexible networks that guarantee superior service quality. By adopting our Mosaic CP and GLDS’s BroadHub®, telMAX is at the forefront of efforts to transform networks to be more responsive to evolving subscriber needs and expectations.”
“Pairing the subscriber-centered functionality of our BroadHub® platform with the control and orchestration capabilities of Adtran’s Mosaic CP enables telMAX to streamline service delivery and elevate the customer experience. BroadHub® is designed to provide comprehensive customer management and billing solutions that manage the complete customer lifecycle. This integration allows telMAX to simplify operations and efficiently deliver superior customer care,” noted Adam Ross Hill, partner alliance manager at GLDS. “Today’s broadband subscribers expect interactions with their service provider to be efficient and accurate. Using our platform, telMAX can automate service delivery and save their technicians and customers valuable time. In addition to boosting subscriber satisfaction, BroadHub® also offers a cost-effective way to enhance operational efficiency, supporting telMAX’s growth and commitment to community empowerment.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716856855/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
